SRR656552
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.373
- KRAS_SIGNALING_DN+0.357
- PANCREAS_BETA_CELLS+0.277
- ESTROGEN_RESPONSE_EARLY+0.217
- SPERMATOGENESIS+0.214
- ESTROGEN_RESPONSE_LATE+0.170
- APICAL_SURFACE+0.165
- HEME_METABOLISM+0.124
- ANGIOGENESIS+0.100
- HEDGEHOG_SIGNALING+0.075
Top 10 suppressed
- MYC_TARGETS_V2-0.437
- NOTCH_SIGNALING-0.422
- CHOLESTEROL_HOMEOSTASIS-0.409
- MYC_TARGETS_V1-0.405
- INTERFERON_ALPHA_RESPONSE-0.379
- DNA_REPAIR-0.371
- E2F_TARGETS-0.341
- MTORC1_SIGNALING-0.331
- G2M_CHECKPOINT-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.301
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NFRXNAFE | ganglioneuroblastoma | — | 0.918 |
| 2 | SRR599448 | GTEX | — | 0.917 |
| 3 | SRR661818 | GTEX | — | 0.914 |
| 4 | SRR614814 | GTEX | — | 0.912 |
| 5 | BS_0X9EGHY2 | low-grade glioma | — | 0.909 |
| 6 | SRR1360104 | GTEX | — | 0.897 |
| 7 | BS_QF5VVZX5 | Ganglioglioma | — | 0.896 |
| 8 | SRR1475257 | GTEX | — | 0.890 |
| 9 | BS_PQ7CQFYR | Ganglioglioma | — | 0.889 |
| 10 | SRR613474 | GTEX | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.373 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.357 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.277 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.217 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.214 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.165 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.124 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.075 | Inavolisib | — uncovered |
| COAGULATION | 0.067 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.065 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.064 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.063 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.061 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.056 | Inavolisib | — uncovered |
| COMPLEMENT | 0.054 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.013 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.005 | Idelalisib | — uncovered |